Veracyte, Inc. (VCYT) financials

Veracyte, Inc. (VCYT) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Veracyte, Inc. reported revenue of $517M, up 16.0% year over year, net income of $66M, diluted EPS of $0.82 and free cash flow of $127M.

Revenue (fiscal 2025)

$517M

Revenue growth (fiscal 2025)

16.0%

Net income (fiscal 2025)

$66M

Diluted EPS (fiscal 2025)

$0.82

Free cash flow (fiscal 2025)

$127M

Veracyte, Inc. files with the U.S. Securities and Exchange Commission under CIK 0001384101, classified as Services-Medical Laboratories.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.